Navigation Links
Merrimack Pharmaceuticals' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
Date:4/8/2013

s were harvested 24 hours after initiating treatment post-randomization and at the end of the study when all treatment arms developed resistance.

Sanofi and Merrimack entered into an exclusive, global license and collaboration agreement for MM-121 in 2009.

About Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

Forward-Looking Statement
To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any statements about Merrimack's strategy, future operations, future financial position and future expectations and plans and prospects for Merrimack, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. In this press release, Merrimack's forward-looking statements include statements about the potential effectiveness of its drug candidates in new indications and its ability to translate preclinical data into future clinical success. Such forward-looking statements involve substantial risks and uncertainties that could cause Merrimack's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implie
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
2. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
3. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
4. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
5. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
6. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
7. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
8. Valeant Pharmaceuticals Provides Update to Recent Event
9. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
10. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
11. European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... FAIRFAX, Va. , Aug. 27, 2014 ... in the legs due to buildup of fatty plaque ... expected in the aging patient population and in incidences ... Radiology offers its Lower Extremity Arterial RevascularizatioN ... Ariz. Endovascular specialists and interested residents and ...
(Date:8/27/2014)... , Aug. 27, 2014 Research ... "Global Pulse Oximeter Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The pulse oximeter market analysis is provided ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316671/Global-Orthopedic-Soft-Tissue-Repair-Devices-Market-2014-2018.html ... soft tissues are the mass of cells that ... types of orthopedic soft tissues such as tendons, ...
Breaking Medicine Technology:LEARN to Treat Peripheral Arterial Disease Patients 2LEARN to Treat Peripheral Arterial Disease Patients 3Global Pulse Oximeter Industry Report 2014 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5
... Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in ... it has dosed the first patient with recent onset ... ongoing Phase I study of QPI-1007, the Company,s proprietary ... The Phase I open-label, dose-escalation study was initiated ...
... PHILADELPHIA, Oct. 20 ERT (Nasdaq: ... for the third quarter 2010 on Thursday, November 4, 2010, ... host a conference call at 5:00 PM EDT that day. ... dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 ...
Cached Medicine Technology:Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 2Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:8/27/2014)... shapes many aspects of our lives. But in addition ... set during development, but can be altered by our ... our parents and grandparents. , The epigenome consists of ... determine whether genes are expressed or silenced. , This ... but also that it may be possible to diagnose ...
(Date:8/27/2014)... August 27, 2014 Tejal K. Gandhi, MD, ... (NPSF) and the NPSF Lucian Leape Institute, is among ... August 25 issue of Modern Healthcare magazine. Also on the ... Andrew Sussman, MD, MBA; NPSF Lucian Leape Institute members ... who is a member of both the Institute and the ...
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps Research ... specific signaling pathway can be associated with alcohol dependence. ... gene, called neurofibromatosis type 1 (Nf1), which TSRI scientists ... new research shows Nf1 regulates gamma-aminobutyric acid (GABA), a ... , "This novel and seminal study provides insights ...
(Date:8/27/2014)... Georgia State University’s Center for ... $600,000 grant from the Maternal and Child Health ... to support implementation of the Autism Plan for ... youth with autism spectrum disorder. , In preparing ... Advisory Council composed of key stakeholders from across ...
(Date:8/27/2014)... West Orange, NJ. August 27, 2014. Kessler Foundation ... cultural competence in brain injury research and rehabilitation. ... Krch, PhD: Issues of cultural diversity in acquired ... by Neurorehabilitation . Drs. Lequerica and ... (TBI) Research at Kessler Foundation and co-investigators for ...
Breaking Medicine News(10 mins):Health News:Scientists map the 'editing marks' on fly, worm, human genomes 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 4Health News:NPSF President Among 100 Most Influential in Health Care 2Health News:NPSF President Among 100 Most Influential in Health Care 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2
... disease has joined poaching and habitat loss as a ... as they have become restricted to ever-smaller populations. Despite ... closest living relatives from ecological extinction are largely failing, ... threats and find innovative solutions. In response to ...
... CHAPEL HILL, N.C. UNC researchers have discovered how ... heart diseases keeps the critical organ from developing properly. According ... distort the shape of cardiac muscle cells so they are ... study also shows that treatment with a drug that regulates ...
... -- (Feb. 6, 2012) -- Researchers at Rice University and ... into cells that form blood vessels. Their success offers hope ... patches to repair infant hearts. "We want to come ... tissue made from stem cells sloughed off by the infant ...
... A new study analyses the influence that certain birth and ... of breast cancer risk. The results reveal that women born ... taller and thinner than the average girl prior to puberty ... increased risk of developing breast cancer. Although the ...
... , SUNDAY, Feb. 5 (HealthDay News) -- More than 60 ... a social networking site, and many spend more than two ... American Academy of Child and Adolescent Psychiatry. Like many ... teens, and parents need to help their children use these ...
... children in the United States were hospitalized due to child ... School of Medicine researchers report in a new study. ... Pediatrics (published online Feb. 6). Several measures ... abuse, including data from Child Protective Services. But until now ...
Cached Medicine News:Health News:Researchers examine consequences of non-intervention for infectious disease in African great apes 2Health News:Researchers examine consequences of non-intervention for infectious disease in African great apes 3Health News:'ROCK' off: Study establishes molecular link between genetic defect and heart malformation 2Health News:Scientists make strides toward fixing infant hearts 2Health News:Scientists make strides toward fixing infant hearts 3Health News:Women born to older mothers have a higher risk of developing breast cancer 2Health News:Safe Social Networking Tips for Teens 2Health News:Children hospitalized at alarming rate due to abuse 2
... High Throughput Screening (UHTS), Analyst GT ... Allows for smooth transfer of assays ... sharing all the detection modalities of ... fluorescence polarization, time-resolved fluorescence, luminescence, absorbance, ...
... Ultra High Throughput Screening (UHTS), Analyst ... performance. Allows for smooth transfer of ... by sharing all the detection modalities ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ...
... exclusively for cell-based assays, the NOVOstar provides ... to the flexibility of an on-board reagent ... plate to plate or from three reagent ... the unit has two injectors that can ...
... cDNA and Oligonucleotides The Tecan GENios ... variety applications that are quantified by Fluorescence, Absorbance ... assays in Microplate formats from 6 to ... Cuvettes Independent whether you have to quantitate ...
Medicine Products: